Since the start of June, Ocular Therapeutix‘s (NSDQ:OCUL) stock price has fallen more than -45%. The company’s founder and chief executive, Amar Swahney, has stepped down, assuming the role of executive chairman, and the FDA has rejected Ocular’s resubmitted new drug application for its hydrogel plug, Dextenza.
Amidst regulatory troubles, Ocular tapped former Mundipharma exec Antony Mattessich to serve in the company’s corner office.
Mattessich has worked for an array of pharma giants, including Novartis(NYSE:NVS) and Bristol-Myers Squibb (NYSE:BMY). In a call today with analysts, Mattessich gave his first comments on how he plans to redirect the Bedford, Mass.-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular’s new CEO to ‘aggressively’ seek partnerships appeared first on MassDevice.